4D Molecular Therapeutics, Inc.

FDMT

Find Out if You Qualify for a Financial Reward by filling out the form below.

4D Molecular Therapeutics, Inc. Form












Stock Fraud Law Center does not share your information with others. There is no cost or obligation for you to submit.

Investigation Details

4D Molecular Therapeutics released the interim results of its Phase 2 PRISM study on Intravitreal 4D-150 on July 17, 2024. Despite the Company billing the results as positive, the stock fell by more than 35.8% in afternoon trading on the same day. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Active Cases

Ticker Symbol Company Name Join Deadline Join
NSSC Napco Security Technologies, Inc. June 24, 2025 Join
CODI Compass Group Diversified Holdings, LLC July 08, 2025 Join
IOVA Iovance Biotherapeutics, Inc. July 14, 2025 Join
OGN Organon & Co. July 22, 2025 Join